Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Voyageur Pharmaceuticals Ltd
Bullboard Posts
User Avatar Image
(0)
•••
Post by tallboyon May 26, 2017 2:05pm
152 Views
Post# 26289439

FAILED MINING PROPERTIES - THE PROOF IS IN THE PAST

FAILED MINING PROPERTIES - THE PROOF IS IN THE PASTLadies and Gentlemen, I hope we've all had a chance to do our homework after hours last night by reviewing the old N-43-101. As we can see clearly in the document, all three barite properties are not NEW and in fact are OLD, and have failed miserably in the past. Their flagship property can only be accessed for 4 months out of the year??? This is a classic B.C. mining property hanging off a sheer cliff face with ZERO ACCESS. This CEO is over 70 years old and does not care about regular shareholders like us. DO NOT BUY THIS PIG at current market price. Be intelligent and wait for the terms of the financing that is what they are CURRENTLY working on. Call them for yourself and you will find the answers you are looking for. 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities